Immunohistochemical profiles of dermatofibroma and dermatofibrosarcoma protuberans: A scoping review

Céline S. C. Hardy[1,2#], Ali S. Razavi[1], Natalie Nunez[1], William Fitzmaurice[1], Loma Dave[1], Amy R. Slutzky[3], Kaitlin Vanderbeck[4], Ramsay Farah[5].

[1] College of Medicine, Upstate Medical University, Syracuse, New York

[2]Department of Microbiology and Immunology, Upstate Medical University, Syracuse, New York, USA

[3] Health Sciences Library, Upstate Medical University, Syracuse, New York

[4]Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario

[5] Division of Dermatology, Upstate Medical University, Syracuse, New York

#Adress correspondence to hardyce@upstate.edu

Keywords: Dermatofibroma, Dermatofibrosarcoma protuberans, Immunohistochemistry

ABSTRACT

This review summarizes the immunohistochemical profiles of dermatofibroma (DF) and dermatofibrosarcoma protuberans (DFSP) as reported by primary literature in the past 10 years. 63 studies were included in the review, with staining information for a total of 99 unique IHC markers reported. The most commonly reported stains were CD34, SMA, S100, and FXIIIa. Most studies applied IHC either to explore descriptive features of DF or DFSP or to determine their utility in diagnostic identification of the lesions. A number of studies applied novel biomarkers which may hold promise for distinguishing DF and DFSP, namely WT1, Cx43, LSP-1, and PHH3, which demonstrated considerable expression differences between the two lesions. This review highlights the need for validation of existing and emerging IHC markers for the diagnosis of DF and DFSP.

1.INTRODUCTION

Dermatofibroma (DF) and dermatofibrosarcoma protuberans (DFSP) are spindle cell lesions with overlapping clinical and histologic features. DF, also known as benign fibrous histiocytoma (BFH), are benign soft tissue tumors with good prognosis. Contrastingly, DFSP are locally aggressive tumors which frequently recur. Additionally, DFSPs may undergo fibrosarcomatous transformation, which portends a higher rate recurrence and increased risk of metastasis[1,2]. Appropriate identification of DFs and DFSPs from each other and their histologic mimics is of critical importance to ensure proper clinical management. Despite their clinical divergence, these two lesions share many histologic and morphologic features. Morphologically, both are spindled lesions which may show increased cellularity and mixed fascicular, whorled or storiform growth patterns. Given their clinical and histologic similarities, it may be challenging to differentiate these two entities on histologic grounds alone, particularly in limited biopsies. Therefore, immunohistochemistry (IHC) is often used to differentiate DF from DFSP and is a mainstay in their diagnosis. Key immunohistochemical markers classically include cluster of differentiation 34 (CD34) and Factor XIIIa (FXIIIa), where CD34 is known to be strongly positive in over 90% of DFSP[3,4], while DFs are known to be negative for CD34 but positive for factor XIIIa [5,6]. Additional markers used to distinguish between these lesions from each other and their mimics include smooth muscle actin (SMA), S-100, and Desmin. Within both DF and DFSP, IHC can

also inform or validate the presence of histologic subtypes, pathogenic/driving gene fusions, and specific pathogenic mechanisms within these lesions.

However, despite the elaborate use of IHC in classifying and studying DF and DFSP, the diagnostic specificity of the currently employed markers is imperfect. Although a number of novel markers have been suggested, constantly emerging literature and suggested biomarkers, coupled with a lack of validated data can lead to confusion about which markers are the most effective. For this reason, we conducted a scoping review of the literature in order to systematically report IHC staining data on these lesions, summarize the utility of existing markers, and highlight emerging markers specifically useful for distinguishing DF and DFSP. An effective summary of the current literature on the IHC staining profiles of these lesions is useful for consolidating information and providing insight into prospective biomarkers which require additional validation.

2.METHODS

2.1 Study design

This review was conducted and reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping Reviews (PRISMA-ScR) guidelines[7]. An a priori study protocol was registered in the Open Science Framework (https://doi.org/10.17605/OSF.IO/92EWY).

2.2 Information sources and search strategy

Four databases – PubMed, Embase (Elsevier), Scopus (Elsevier), and the Cochrane Library – were searched for relevant articles. For each database, key concepts were defined using combinations of controlled vocabulary (where available) and keywords, to maximize search sensitivity. The PubMed search strategy is given below; full search strategies are given in Appendix X.

PubMed search strategy:

("Histiocytoma, Benign Fibrous"[Mesh] OR "Dermatofibrosarcoma"[Mesh] OR “histiocytoma*”[tiab] OR dermatofibro*[tiab] OR DFSP[tiab] OR “nodular subepidermal fibrosis”[tiab])

AND

("Immunohistochemistry"[Mesh] OR immunohistochem*[tiab] OR IHC[tiab] OR immunostain*[tiab])

Database search strategies limited search results to publication dates over the past 20 years (2003-present). Final searches for all databases were run on June 24, 2024.

2.3 Eligibility criteria

Studies were selected for inclusion in the review if they:

- evaluated protein expression by immunohistochemistry (IHC), specifically immunoperoxidase staining, of tissue specimens from human subjects of histologically confirmed cases of cutaneous DF (including benign fibrous histiocytoma, cutaneous fibrous histiocytoma, and epithelioid fibrous histiocytoma) or DFSP;
- reported the number of lesions evaluated and the fraction of lesions positive or negative for a given marker for greater than 5 lesions;
- focused on evaluating the tumor cell compartment (as opposed to stromal or immune cell profiling); and
- were published in English, French, or Spanish.

The following types of studies were excluded from the review: review articles, case reports, conference abstracts, in vitro studies, and animal studies.

2.4 Article screening

Results from all database searches were uploaded to Covidence (Veritas Health Innovation, Melbourne, Australia). Duplicate records were identified and removed automatically by Covidence, with all duplicate pairs manually confirmed (AS). Then two reviewers (AR, WF, NN, and/or LD) independently screened each title/abstract for inclusion in the review, with any conflicts resolved via discussion with content experts (RF and/or KV). After title/abstract screening was complete, a decision was made to limit the review to studies published over the past 10 years (2013-present), and to exclude case studies and case series evaluating fewer than five lesions. These decisions were made both due to practical/time constraints and in consideration of the relevance of IHC markers evaluated, pertinence and consistency of antibody

clones and staining protocols used. Full-text articles were then screened independently by two reviewers (AR, WF, NN, and/or CH), with any conflicts resolved as described above.

2.5 Data abstraction

Data collection was performed first by one of two independent reviewers (CH, AR) and then independently verified by the second reviewer. The following data were collected and charted using Microsoft Excel:

- Study characteristics (article title, publication date, study aim, study geographic location)
- Lesion information (type and number of lesions studied, sample/specimen type, histologic information if available)
- IHC characteristics (IHC stains performed, method of IHC evaluation, specific antibodies used, staining expression results for lesions of interest)

3.RESULTS

3.1 Selection and characteristics of sources of evidence

Database searches identified 2506 distinct articles. Following title/abstract and full text screening, 63 articles were selected for inclusion in the review (**Fig. 1**). Of those 63 studies, 15 contained IHC data for DF only, 28 for DFSP only, and 20 studies contained data for both DF and DFSP. Complete characteristics of all articles described in this study -- including geographic location, date of sample collection, and study aim -- are summarized in supplemental **Table S1.**

3.2 Immunohistochemical markers applied in DF and DFSP

Across all studies, a total of 99 IHC markers were evaluated, of which the most discussed markers included CD34, SMA, S100, FXIIIa, Desmin, and Ki-67 (**Fig. 2**). CD68, ALK, EMA, and PanCK were also frequently discussed (**Fig. 2**). The purpose of IHC application in these studies could be broadly categorized as descriptive, diagnostic, or prognostic. Summary tables of IHC biomarkers applied and their indication or purpose of application in DF and DFSP are summarized in **Table 1** and **Table 2**, respectively. The majority of IHC markers were applied for descriptive or diagnostic purposes. Descriptive studies focused primarily on characterizing expression of a given marker in specific entities, determining associations of expression with variant histology, or evaluating the role of expression in disease pathogenesis. Of the studies

evaluating IHC staining with respect to its diagnostic utility, 37 studies assessed a role for IHC in distinguishing histologic mimics from either DF or DFSP, while 15 studies contained data focused specifically on distinguishing DF and DFSP from each other.

3.3 Immunohistochemical markers for distinguishing DF and DFSP

When focusing on studies aiming to characterize differences in immunohistochemical expression between DF and DFSP (n=13), a total of 30 IHC markers were evaluated. CD34 and Factor XIIIa were the most frequently employed markers for distinguishing DF and DFSP in the reviewed studies (**Fig. 3**). Summary statistics of the staining expression of classical markers in DF compared to DFSP across all studies are provided in **Table 3**. CD34 was frequently strongly positive in DFSPs (95.8%), while negative in DF (15.5%), and contrastingly Factor XIIIa was positive in DF (86.2%) but more frequently negative in DFSP (24.9%) (**Table 3**). SMA, ALK, CD99, and CD68 were more frequently positive in DF than DFSP, while S100 and Desmin tended to be negative in both (**Table 3**). Many studies also provided data regarding more novel markers evaluated for distinguishing between the two lesions, these included: WT1, ERG, D2-40, PHH3, p75, Cx43, FGF2, FGFR4, LSP-1, p16, and Ki-67 (**Table 4).** Of these, studies evaluating WT1, Cx43 and LSP-1 demonstrated the greatest difference in expression between DF and DFSP. Complete expression data for all markers across all studies are available in supplemental **Table S2.**

4.DISCUSSION

In this study, we summarize the applications of IHC markers in DF and DFSP and their utility for distinguishing these lesions as reported in the literature over the past 10 years. In this review a total of 99 unique IHC markers were reported in the 63 studies evaluated. Interpretation of the expression data of these markers and the utility of key markers for distinguishing DF and DFSP will be elaborated upon in the following sections.

4.1 Accuracy of classical markers for distinguishing DF and DFSP

Classical markers for diagnosis of DF and DFSP such as CD34, FXIIIa, S-100, and Desmin all demonstrated expression in expected proportions and patterns according to the literature[8]. However, it is important to note that despite these overall trends there was marked intra-study

186 variability for most markers. For example, even CD34, one of the most specific markers positive
187 in DFSP, was weakly or focally positive in ~15% of DFs[9–11]. Most commonly, conventional DFs
188 did show negativity for CD34, however many DFs which contained variant histology were
189 specifically noted to have focal CD34 expression. This highlights previous observations that
190 application of CD34 alone is insufficient, and the need for additional markers to clarify the
191 identity of lesions where CD34 expression is ambiguous or present focally. Interestingly,
192 expression of classical markers CD99 and CD68 were reported of variable diagnostic utility to
193 distinguish DF and DFSP. While one study showed that DFs have higher frequency of CD99
194 positivity compared to DFSPs[12] and additional data supports there being evidently low
195 expression of CD99 in DFSPs (0% positivity)[13,14], data from Song et al. shows 50% positivity in
196 both lesions[12–15]. Altogether, there remains work to be done to determine the expression in DF
197 compared to DFSP of classical markers using additional sample sets. Beyond these diagnostic
198 applications, there is a need to better understand the expression of classical markers within these
199 lesion types in regions with variant histology.
200
201 **4.2 Emerging markers for distinguishing DF and DFSP**
202 Given the imperfect specificity of classical markers, there is an inherent need to identify and
203 validate the utility of more novel markers for diagnostic dilemmas. A number of the reviewed
204 studies assessed a role for novel markers in distinguishing DF and DFSP from each other or their
205 mimics. Promising emerging IHC markers included WT1, LSP-1, Cx43, and a combined Ki67
206 and PHH3 score, which warrant further investigation[16–19].Piombino et al. assessed the expression
207 of WT1, a master transcriptional/translational regulator in cell differentiation in a series of soft
208 tissue neoplasms of mesenchymal origin. They found that cytoplasmic WT1 expression was
209 absent in all evaluated DFs, but positive in 94.7% of DFSPs[16]. Like WT1, connexin 43 (Cx43)
210 was evaluated by Fernandez-Flores et al. because of its suspected role in pathogenesis.
211 Specifically, with respect to propensity for invasion given that connexins are involved in
212 mediating cell-cell adhesion. Cx43 demonstrated excellent specificity for the lesions, with 100%
213 positivity in DF and 0% positivity in DFSP[17]. Another promising marker studied was Leukocyte
214 specific protein 1 (LSP-1) which was also highly positive in DF, while negative in DFSP[18].
215 Although Ki-67 is traditionally thought of as a prognostic, rather than diagnostic
216 biomarker, Agarwal et al. identify potential utility of Ki-67 for distinguishing DF and DFSP in a

217 combined scoring system with phosphohistone H3 (PHH3)[19]. PHH3 is expressed in M phase and
218 is therefore useful in determining mitotic counts. The goal of this study was to assess the utility
219 of a combined scoring system incorporating both the Ki67 index and PHH3 mitotic count, where
220 they found that the mean Ki67 proliferation index and mitotic count were significantly higher in
221 DF compared to DFSP[19]. Interestingly, this study may highlight that the integration of multiple
222 features or biomarkers can provide more comprehensive information than looking for one "silver
223 bullet" IHC marker to clarify the diagnosis.
224 D2-40 is another emerging marker for which a number of studies suggested utility,
225 however these data were contradictory and require additional validation. A number of studies
226 suggest D2-40 for aiding in the differential diagnosis of DF and DFSP, where D2-40 is positive
227 in DF and negative in DFSP[9,20]. However, data from Song et al. demonstrated only 33%
228 positivity in DF[15]. Like D2-20, markers such as ERG, CD10, and p75 have some data to indicate
229 utility, but require further investigation due to conflicting data, or low sample numbers. Across
230 all markers, it should be noted that small sample size, differences in antibody clones, staining
231 protocols, and staining evaluation methodology remain a challenge that likely contribute greatly
232 to the observed variability across studies evaluating a given marker.
233
234 **5. Conclusions**
235 In this review, we report the IHC expression in DF and DFSP of traditional diagnostic markers
236 as well as novel markers which may hold diagnostic utility according to the literature from the
237 past 10 years. Of the markers discussed with diagnostic relevance, traditional markers such as
238 CD34, SMA, and FXIIIa were the most common and demonstrated expected expression patterns
239 in DF and DFSP. Additionally, studies investigated novel markers for distinguishing DF and
240 DFSP such as WT1, Cx43, LSP-1, and PHH3/Ki-67. Future studies should seek to continue
241 investigating the expression of these markers and their potential utility for diagnostic application.
242
243 **Author contributions**:
244 Céline S. C. Hardy, Conceptualization, Data curation, Formal analysis, Investigation,
245 Methodology, Visualization, Writing – original draft, Writing – review and editing | Ali S.
246 Razavi, Conceptualization, Data curation, Investigation, Methodology, Writing – review and
247 editing | Natalie Nunez, Data curation, Investigation, Writing – review and editing | William

Fitzmaurice, Data curation, Investigation, Writing – review and editing | Loma Dave, Data curation, Investigation, Writing – review and editing | Amy R. Slutzky, Data curation, Methodology, Supervision, Writing – review and editing | Kaitlin Vanderbeck, Conceptualization, Data curation, Investigation, Methodology, Supervision, Writing – review and editing | Ramsay Farah, Conceptualization, Investigation, Methodology, Supervision, Writing – review and editing

Data availability

Data supporting the findings of this study are available within the article and/or its supplementary material.

REFERENCES

1. Abbott JJ, Oliveira AM, Nascimento AG. The Prognostic Significance of Fibrosarcomatous Transformation in Dermatofibrosarcoma Protuberans. *Am J Surg Pathol*. 2006;30(4). https://journals.lww.com/ajsp/fulltext/2006/04000/the_prognostic_significance_of_fibrosarcomatous.2.aspx

2. Reifs CMA, Salido-Vallejo R. Dermatofibrosarcoma protuberans with fibrosarcomatous transformation. *An Bras Dermatol*. 2016;91(5):700-701. doi:10.1590/abd1806-4841.20164886

3. Abenoza P, Lillemoe T. CD34 and Factor XIII a in the Differential Diagnosis of Dermatofibroma and Dermatofibrosarcoma Protuberans: *Am J Dermatopathol*. 1993;15(5):429-434. doi:10.1097/00000372-199310000-00003

4. Llombart B, Sanmartín O, López-Guerrero JA, et al. Dermatofibrosarcoma protuberans: clinical, pathological, and genetic (*COL1A1-PDGFB*) study with therapeutic implications. *Histopathology*. 2009;54(7):860-872. doi:10.1111/j.1365-2559.2009.03310.x

5. CERIO R, SPAULL J, JONES EW. Histiocytoma cutis: a tumour of dermal dendrocytes (dermal dendrocytoma). *Br J Dermatol*. 1989;120(2):197-206. doi:10.1111/j.1365-2133.1989.tb07783.x

6. RAMANI P, BRADLEY NJ, FLETCHER CDM. QBEND/10, a new monoclonal antibody to endothelium: assessment of its diagnostic utility in paraffin sections. *Histopathology*. 1990;17(3):237-242. doi:10.1111/j.1365-2559.1990.tb00713.x

7. Tricco AC, Lillie E, Zarin W, et al. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. *Ann Intern Med*. 2018;169(7):467-473. doi:10.7326/M18-0850

281 8. Haycox CL, Odland PB, Olbricht SM, Piepkorn M. dermatofibrosarcoma protuberans with
282 practical applications for diagnosis and treatment.

283 9. Sadullahoglu C, Dere Y, Atasever TR, Oztop MT, Karaaslan O. The role of cd34 and d2-40 in
284 the differentiation of dermatofibroma and dermatofibrosarcoma protuberans. *Turk J*
285 *Pathol*. Published online 2017. doi:10.5146/tjpath.2017.01402

286 10. Liu F, Wang H, Wu G, Li C. Clinical and pathological studies of eight cases of lipidized fibrous
287 histiocytoma. *Exp Ther Med*. 2023;25(2):93. doi:10.3892/etm.2023.11792

288 11. West KL, Cardona DM, Su Z, Puri PK. Immunohistochemical Markers in Fibrohistiocytic
289 Lesions: Factor XIIIa, CD34, S-100 and p75. *Am J Dermatopathol*. 2014;36(5).

290 12. Kazlouskaya V, Malhotra S, Kabigting FD, Lal K, Elston DM. CD99 Expression in
291 Dermatofibrosarcoma Protuberans and Dermatofibroma. *Am J Dermatopathol*.
292 2014;36(5):392-396. doi:10.1097/DAD.0b013e3182a15f3e

293 13. Dai Z, He Y, Zhang X, et al. Head-and-neck dermatofibrosarcoma protuberans: Survival
294 analysis and Clinically relevant immunohistochemical indicators. *Oral Dis*. 2024;30(3):1040-
295 1051. doi:10.1111/odi.14495

296 14. Zhang Z, Lu Y, Shi C, Chen M, He X, Zhang H. Pediatric dermatofibrosarcoma protuberans: A
297 clinicopathologic and genetic analysis of 66 cases in the largest institution in Southwest
298 China. *Front Oncol*. 2023;13:1017154. doi:10.3389/fonc.2023.1017154

299 15. Song JS, Kim EJ, Park CS, Cho KJ. Dermatofibrosarcoma Protuberans: An Immunomarker
300 Study of 57 Cases That Included Putative Mesenchymal Stem Cell Markers. *Appl*
301 *Immunohistochem Mol Morphol*. 2017;25(8):586-591. doi:10.1097/PAI.0000000000000348

302 16. Piombino E, Broggi G, Barbareschi M, et al. Wilms' Tumor 1 (WT1): A Novel Immunomarker
303 of Dermatofibrosarcoma Protuberans—An Immunohistochemical Study on a Series of 114
304 Cases of Bland-Looking Mesenchymal Spindle Cell Lesions of the Dermis/Subcutaneous
305 Tissues. *Cancers*. 2021;13(2):252. doi:10.3390/cancers13020252

306 17. Fernandez-Flores A, Varela-Vazquez A, Mayan MD, Fonseca E. Connexin 43 in
307 Dermatofibroma and Dermatofibrosarcoma Protuberans: Diagnostic, Pathogenic, and
308 Therapeutic Implications. *Am J Dermatopathol*. 2023;45(12):812-815.
309 doi:10.1097/DAD.0000000000002562

310 18. Jin SY, Choi JS, Choi YL, Choi YL, Kim DH, Lee SH. Identification of Leukocyte-Specific Protein
311 1-Positive Cells: A Clue to the Cell of Origin and a Marker for the Diagnosis of
312 Dermatofibroma. *Ann Dermatol*. 2015;27(2):157. doi:10.5021/ad.2015.27.2.157

313 19. Agarwal A, Gopinath A, Tetzlaff MT, Prieto VG. Phosphohistone-H3 and Ki67: Useful
314 Markers in Differentiating Dermatofibroma From Dermatofibrosarcoma Protuberans and

315 Atypical Fibrohistiocytic Lesions. *Am J Dermatopathol*. 2017;39(7):504-507.
316 doi:10.1097/DAD.0000000000000690

317 20. Aslam M, Khan FW, Chughtai AS, Naeem A, Bashir A, Khan A. Frequency of Expression of
318 D240 in Dermatofibroma – A diagnostic study. *Pak J Med Health Sci*. 2022;16(1):37-39.
319 doi:10.53350/pjmhs2216137

320 21. Hung YP, Fletcher CDM, Hornick JL. FOSB is a Useful Diagnostic Marker for Pseudomyogenic
321 Hemangioendothelioma. *Am J Surg Pathol*. 2017;41(5):596-606.
322 doi:10.1097/PAS.0000000000000795

323 22. Berklite L, John I, Ranganathan S, Parafioriti A, Alaggio R. SOX9 Immunohistochemistry in
324 the Distinction of Angiomatoid Fibrous Histiocytoma From Histologic Mimics: Diagnostic
325 Utility and Pitfalls. *Appl Immunohistochem Mol Morphol*. 2020;28(8):635-640.
326 doi:10.1097/PAI.0000000000000809

327 23. Pan H, Byers J, Yin H, et al. The utility of TLE1 and BCOR as immunohistochemical.

328 24. Cheah AL, Billings SD, Goldblum JR, Carver P, Tanas MZ, Rubin BP. STAT6 rabbit monoclonal
329 antibody is a robust diagnostic tool for the distinction of solitary fibrous tumour from its
330 mimics. *Pathology (Phila)*. 2014;46(5):389-395. doi:10.1097/PAT.0000000000000122

331 25. Abdaljaleel MYO, North JP. Sclerosing Dermatofibrosarcoma Protuberans Shows Significant
332 Overlap With Sclerotic Fibroma in Both Routine and Immunohistochemical Analysis: A
333 Potential Diagnostic Pitfall. *Am J Dermatopathol*. 2017;39(2):83-88.
334 doi:10.1097/DAD.0000000000000584

335 26. Zhou L, Xu H, Zhou J, et al. Nuclear TFE3 expression is a diagnostic marker for Desmoid-type
336 fibromatosis. *Diagn Pathol*. 2019;14(1):34. doi:10.1186/s13000-019-0814-4

337 27. Kazakov DV, Kyrpychova L, Martinek P, et al. ALK Gene Fusions in Epithelioid Fibrous
338 Histiocytoma: A Study of 14 Cases, With New Histopathological Findings. *Am J*
339 *Dermatopathol*. 2018;40(11):805-814. doi:10.1097/DAD.0000000000001085

340 28. Moayed-Alaei L, Vargas AC, Adybeik D, Maclean F, Moir D. Analyzing the morphological
341 spectrum of epithelioid fibrous histiocytoma and the immunohistochemical performance of
342 the ALK D5F3 and ALK1 clones. *Hum Pathol*. 2022;120:46-56.
343 doi:10.1016/j.humpath.2021.12.004

344 29. Yamada Y, Ichiki T, Susuki Y, et al. Diagnostic utility of ERG immunostaining in
345 dermatofibroma. *J Clin Pathol*. 2023;76(8):536-540. doi:10.1136/jclinpath-2022-208158

346 30. Hengy M, Veenstra J, Perry K, Ozog DM, Friedman BJ. ETS-related Gene (ERG) is
347 Differentially Expressed in Dermatofibroma (Fibrous Histiocytoma) as Compared With
348 Dermatofibrosarcoma Protuberans and Hypertrophic Scars: A Pilot Immunohistochemical

349 Study. *Appl Immunohistochem Mol Morphol*. 2022;30(6):453-458.
350 doi:10.1097/PAI.0000000000001030

351 31. Kouki N, Ben Rejeb S, Cherif I, et al. Comparative expression profile of CD10 and cyclin D1 in
352 cutaneous histiocytofibroma and dermatofibrosarcoma. *J Immunoassay Immunochem*.
353 2021;42(4):347-358. doi:10.1080/15321819.2020.1868000

354 32. Nam KH, Park SW, Yun SK. A clinicohistopathological analysis of cutaneous fibrous
355 histiocytomas of the finger. *Indian J Dermatol*. 2020;65(5):401. doi:10.4103/ijd.IJD_366_18

356 33. Ishigami T, Hida Y, Matsudate Y, Murao K, Kubo Y. The involvement of fibroblast growth
357 factor receptor signaling pathways in dermatofibroma and dermatofibrosarcoma
358 protuberans. *J Med Invest*. 2013;60(1.2):106-113. doi:10.2152/jmi.60.106

359 34. Park S, Cho S, Kim M, et al. Dermatofibrosarcoma protuberans: A retrospective study of
360 clinicopathologic features and related Akt/mTOR, STAT3, ERK, cyclin D1, and PD-L1
361 expression. *J Am Acad Dermatol*. 2018;79(5):843-852. doi:10.1016/j.jaad.2018.05.016

362 35. Sandell RF, Carter JM, Folpe AL. Solitary (juvenile) xanthogranuloma: a comprehensive
363 immunohistochemical study emphasizing recently developed markers of histiocytic lineage.
364 *Hum Pathol*. 2015;46(9):1390-1397. doi:10.1016/j.humpath.2015.05.025

365 36. Cammareri C, Beltzung F, Michal M, et al. PRAME immunohistochemistry in soft tissue
366 tumors and mimics: a study of 350 cases highlighting its imperfect specificity but potentially
367 useful diagnostic applications. *Virchows Arch*. 2023;483(2):145-156. doi:10.1007/s00428-
368 023-03606-6

369 37. Campione E, Di Prete M, Costanza G, et al. Increased Occurrence of Cutaneous Leiomyomas
370 and Dermatofibromas in Patients with Uterine Leiomyomas without Fumarate Hydratase
371 Gene Mutations. *Dermatopathology*. 2023;10(3):231-243.
372 doi:10.3390/dermatopathology10030032

373 38. Smith EH, Lowe L, Harms PW, Fullen DR, Chan MP. Immunohistochemical evaluation of P16
374 expression in cutaneous histiocytic, fibrohistiocytic and undifferentiated lesions. *J Cutan*
375 *Pathol*. 2016;43(8):671-678. doi:10.1111/cup.12730

376 39. Li FZ, Ye Q, Ran LW, Fang S. Adipophilin expression in skin lesions with clear cell histology. *J*
377 *Clin Pathol*. 2022;75(9):627-631. doi:10.1136/jclinpath-2021-207443

378 40. Jahanseir K, Xing D, Greipp PT, et al. PDGFB Rearrangements in Dermatofibrosarcoma
379 Protuberans of the Vulva: A Study of 11 Cases Including Myxoid and Fibrosarcomatous
380 Variants. *Int J Gynecol Pathol*. 2018;37(6):537-546. doi:10.1097/PGP.0000000000000472

381 41. Nakamura I, Kariya Y, Okada E, et al. A Novel Chromosomal Translocation Associated With
382 *COL1A2 - PDGFB* Gene Fusion in Dermatofibrosarcoma Protuberans: PDGF Expression as a

383 New Diagnostic Tool. *JAMA Dermatol*. 2015;151(12):1330.
384 doi:10.1001/jamadermatol.2015.2389

385 42. Afifi MM, Elnouaem MI, Omar EM, El-Komary I. Oral and Extraoral Intermediate Tumors:
386 Are MMP-9 and Ki-67 Biomarkers Correlated to Their High Recurrence Rates? *Appl*
387 *Immunohistochem Mol Morphol*. 2020;28(3):229-236. doi:10.1097/PAI.0000000000000703

388 43. Vivero M, Doyle LA, Fletcher CDM, Mertens F, Hornick JL. GRIA 2 is a novel diagnostic
389 marker for solitary fibrous tumour identified through gene expression profiling.
390 *Histopathology*. 2014;65(1):71-80. doi:10.1111/his.12377

391 44. Saeed O, Zhang S, Cheng L, Lin J, Alruwaii F, Chen S. STAT6 Expression in Solitary Fibrous
392 Tumor and Histologic Mimics: a Single Institution Experience. *Appl Immunohistochem Mol*
393 *Morphol*. 2020;28(4):311-315. doi:10.1097/PAI.0000000000000745

394 45. Xu S, Zhao L, Wang J. Atrophic dermatofibrosarcoma protuberans: a clinicopathological
395 study of 16 cases. *Pathology (Phila)*. 2019;51(6):615-620. doi:10.1016/j.pathol.2019.06.002

396 46. Thangaiah JJ, Westling BE, Roden AC, et al. Loss of dimethylated H3K27 (H3K27me2)
397 expression is not a specific marker of malignant peripheral nerve sheath tumor (MPNST):
398 An immunohistochemical study of 137 cases, with emphasis on MPNST and melanocytic
399 tumors. *Ann Diagn Pathol*. 2022;59:151967. doi:10.1016/j.anndiagpath.2022.151967

400 47. Cleven AHG, Sannaa GAA, Briaire-de Bruijn I, et al. Loss of H3K27 tri-methylation is a
401 diagnostic marker for malignant peripheral nerve sheath tumors and an indicator for an
402 inferior survival. *Mod Pathol*. 2016;29(6):582-590. doi:10.1038/modpathol.2016.45

403 48. Pukhalskaya T, Smoller BR. TLE1 expression fails to distinguish between synovial sarcoma,
404 atypical fibroxanthoma, and dermatofibrosarcoma protuberans. *J Cutan Pathol*.
405 2020;47(2):135-138. doi:10.1111/cup.13596

406 49. Kreicher KL, Honda KS, Kurlander DE, Bordeaux JS. Hormone receptor expression in patients
407 with dermatofibrosarcoma protuberans. *J Am Acad Dermatol*. 2016;75(6):1205-1209.
408 doi:10.1016/j.jaad.2016.07.011

409 50. Meng T, Shi X, Wu S, Luo Y, Wang X, Long X. Hormone receptors analysis in Chinese patients
410 with dermatofibrosarcoma protuberans. *J Surg Oncol*. 2018;118(1):157-166.
411 doi:10.1002/jso.25117

412 51. Hiraki-Hotokebuchi Y, Yamada Y, Kohashi K, et al. Alteration of PDGFRβ-Akt-mTOR pathway
413 signaling in fibrosarcomatous transformation of dermatofibrosarcoma protuberans. *Hum*
414 *Pathol*. 2017;67:60-68. doi:10.1016/j.humpath.2017.07.001

415 52. Brčić I, Godschachner TM, Bergovec M, et al. Broadening the spectrum of NTRK rearranged
416 mesenchymal tumors and usefulness of pan-TRK immunohistochemistry for identification
417 of NTRK fusions. *Mod Pathol*. 2021;34(2):396-407. doi:10.1038/s41379-020-00657-x

53. Xiong JX, Cai T, Hu L, et al. Risk factors related to postoperative recurrence of dermatofibrosarcoma protuberans: A retrospective study and literature review. *World J Clin Cases*. 2021;9(20):5442-5452. doi:10.12998/wjcc.v9.i20.5442

54. Han Q, Chen M, Yang J, Du T, Peng H. Dermatofibrosarcoma protuberans of the face: A clinicopathologic and molecular study of 34 cases. *JDDG J Dtsch Dermatol Ges*. 2022;20(11):1463-1473. doi:10.1111/ddg.14882

55. Zhang X, Sun D, Zheng H, et al. Comprehensive analysis of transcriptome characteristics and identification of TLK2 as a potential biomarker in dermatofibrosarcoma protuberans. *Front Genet*. 2022;13:926282. doi:10.3389/fgene.2022.926282

56. Adem D, Yazici S, Ozsen M, et al. The Ki-67 proliferation index predicts recurrence-free survival in patients with dermatofibrosarcoma protuberans. *Bosn J Basic Med Sci*. Published online October 20, 2020. doi:10.17305/bjbms.2020.5088

57. Serra-Guillén C, Llombart B, Nagore E, et al. High immunohistochemical nestin expression is associated with greater depth of infiltration in dermatofibrosarcoma protuberans: a study of 71 cases. *J Cutan Pathol*. 2013;40(10):871-878. doi:10.1111/cup.12203

TABLES

Table 1. Immunohistochemical biomarkers applied in DF and their primary indication as evaluated in the studies reviewed.

Indication	Markers	Utility/Findings
Diagnostic	CD34, FXIIIa, S100, SMA, Desmin, Vimentin	Classical diagnostic markers
	FOSB	Distinguish from pseudomyogenic hemagioendothelioma[21]
	SOX9	Distinguish from AFH[22]
	TLE1, BCOR	Distinguish from AFH[23]
	STAT6	Distinguish from SFT[24]
	MITF, NKI/C3	Compare to expression in cellular neurothekoma[25]
	TFE3	Compare expression to desmoid type fibromatosis[26] and evaluate histopathologic features[27,28]
	ERG[29,30], WT1[16], p75[11], D2-40[9,20]	Distinguish from DFSP and its mimics
	CD10[15,31], CCND1[31], LSP1[18], CD68[10,18,28,32]	Distinguish from DFSP
	CD99	Distinguish from DFSP and describe expression[12,15]
Descriptive	MUC4	Describe features of lipidized fibrous histiocytoma[10]
	FGFR1-4, FGF2	Understand expression patterns and role in pathogenesis[33]
	Akt, mTOR, STAT3, ERK, CCND1	Understand expression pattern and assess role in recurrence[34]
	CD163[28,35], CD11c,CD31,CD45, lysozyme, and CD4[35]	Characterize the immunophenotype of solitary xanthogranuloma in comparison to its

		differential diagnoses (including BFH)
	NICD[35], PRAME[36]10/23/24 7:39:00 PM	Describe expression in various fibroproliferative diseases
	TGFb, TGFRb-1/2, SMAD3, VDR	Describe expression in DF, cutaneous leiomyomas, and uterine leiomyomas[37]
	PanCK[10,28], SOX10, p63, and EMA[28], P16[14,38], P53[39,40], CD105, CD133, Oct3/4, CD117, and ALK[15], PDGFRα/β, PDGFα/β[15,41], Nestin[41]	Describe expression
Prognostic	Ki-67, MMP9	Association with high recurrence rate[42]

Table 2. Immunohistochemical markers applied in DFSP and their primary indication as evaluated in the studies reviewed.

Indication	**Markers**	**Utility/Findings**
Diagnostic	CD34, FXIIIa, SMA, S100, Desmin, Vimentin	Classical diagnostic markers
	GRIA2[43], STAT6[24,44,45]	Distinguish from SFT[24] and describe expression
	H3K27me3, H3K27me2	Distinguish PNST from its mimics[46,47]
	TLE1	Distinguish AFX and synovial sarcoma[48]
	EVG	Compare to expression in sclerotic fibroma and perineuroma[25]
	ERG	Distinguish from its mimics[29,30]
	WT1	Distinguish from DFSP and its mimics[16]
	LSP1[18], CD68[12,45], p75[11], D2-40[9,15], CD10[15,31,39], CCND1[31,34]	Distinguish from DF
Descriptive	Melan-A[12,45], PanCK and HMB45[45]	Study features of atrophic DFSP
	ER, PR	Describe role in pathogenesis/tumor growth[49,50]
	FGFR1-4, FGF2	Understand expression patterns and role in pathogenesis[33]
	Akt[34,51], mTOR, STAT3, and ERK [34], p-4EBP1, p-S6RP, p-and mTOR[51]	Understand expression patterns and role in pathogenesis
	NTRK[52]	Describe expression in soft tissue sarcomas
	P16[14,38]	Describe expression patterns
	BCL-2[13,14,53], CD99[12–15], p63, Myogenin[14], MSA[13]	Describe expression patterns/understand clinicopathologic features
	EMA	Describe expression[14,25,54] and assess relevance to fibrosarcomatous transformation[39]
	CD105, CD133, ALK, Oct3/4, and CD117[15], PDGFRα/β[13,15,51], PDGFα/β[13,15], FAM118B and TLK2[55], PRAME[36]	Describe expression
Prognostic	Ki-67	Independent predictor of RFS[56]
	EZH2, EGFR, PD-L1, VEGF	Investigation as therapeutic targets [13]
	Nestin[41,57]	Association of expression with degree of invasion[57]

Table 3. General trends of immunohistochemical expression for classical/ well described key markers for distinguishing DF and DFSP

Listed markers	**DF**		**DFSP**	
	General expression (+/-)	In evaluated studies n/total, (%)	General expression (+/-)	In evaluated studies n/total, (%)
CD34	-	35/226 (15.5)	+	980/1023 (95.8)

FXIIIa	+	163/189(86.2)	-	28/108(25.9)
SMA	+	63/183 (34.4)	-	26/370(7)
S100	-	15/114 (13.1)	-	12/432(2.8)
ALK	+	71/154 (46.1)	-	0/57(0)
CD99	+	30/36(83.3)	-	56/176(31.8)
CD68	+	25/59(42.4)	-	5/27(18.5)
Desmin	-	0/41(0)	-	0/332 (0)
Vimentin	N/A	N/A	+	123/126(97.6)

*n/total where n=number of positive samples.

Table 4. General trends of immunohistochemical expression for novel/emerging markers evaluated in distinguishing DF and DFSP

Marker	**Evidence** (n positive/total)	**Study**
WT1	Negative in DF (0/15), positive in DFSP (54/57)	Piombino et al. (2021)[16]
Cx43	Positive in DF (16/16), Negative in DFSP (0/13 positive)	Fernandez-flores et al. (2023)[17]
LSP-1	Positive in DF (18/20), negative in DFSP (2/20)	Jin et al. (2015)[18]
ERG	87/97 DF positive with variable (50-89% cells) positive, 0/64 DFSP positive	Yamada et al. (2023)[29]
	15/15 DF positive, 6/9 DFSP positive	Hengy et al. (2022)[30]
PHH3	DF mean mitotic count 1.8 mm^2, DFSP mean mitotic count 0.5/mm^2	Agarwal et al. (2017)[19]
Ki-67	Mean proliferative index in DF: 39.2mm^2, DFSP: 12.6 mm^2	Agarwal et al. (2017)[19]
P75	0/30 DF positive, 17/32 DFSP positive	West et al. (2014)[11]
D2-40	Positive in DF (49/70)	Aslam et al. (2021)[20]
	Positive in DF (23/30) and negative in DFSP (2/15 positive)	Sadullahoglu 2017[9]
	DF 4/12 positive, DFSP 2/57 positive	Song et al. (2017)[15]
Oct3/4	0/12 DF, 0/57 DFSP	Song et al. (2017)[15]
CD10	12/12 DF, 23/57 DFSP	Song et al. (2017)[15]
	13/15 DF, 15/15 DFSP	Kouki et al. (2021)[31]
	12/15 DF, 15/15 DFSP	Kouki et al. (2021)[30]
FGF2 and FGFR4	Positive in DF (20/20), variable expressivity in DFSP (4/6 positive)	Ishigami et al. (2013)[33]
FGFR1-3	All cases negative in both DF (0/20) and DFSP (0/6)	Ishigami et al. (2013)[33]

P16	Positive in both DF (18/19) and DFSP (4/5)	Smith et al. (2016)[38]

452
453

454 **FIGURE LEGENDS**

455 **Figure 1. PRISMA flow diagram indicating the article selection process.**

456 **Figure 2. Frequency of IHC biomarker use across all studies (n=63).** Bar plot indicating the
457 frequency of IHC biomarkers assessed across all studies. Bars indicate the number of studies
458 which evaluated a given marker.

459 **Figure 3. Frequency of IHC biomarker use in studies distinguishing between DF and DFSP**
460 **(n=15).** Bar plot indicating the frequency of IHC biomarkers assessed across studies which
461 aimed to differentiate DF and DFSP. Bars indicate the number of studies which evaluated a
462 given marker.

463

Figure 1.


Identification
Studies from databases/registers (n = 3150)
PubMed (n = 1362)
Embase (n = 1003)
Scopus (n = 783)
Cochrane Library (n = 2)
References removed (n = 644)
Duplicates identified manually (n = 6)
Duplicates identified by Covidence (n = 638)
Marked as ineligible by automation tools (n = 0)
Other reasons (n = 0)
Screening
Studies screened (n = 2506)
Studies excluded (n = 1718)
Studies sought for retrieval (n = 788)
Studies not retrieved (n = 0)
Studies assessed for eligibility (n = 788)
Studies excluded (n = 725)
Case study (n = 301)
Case series (n = 24)
Exceeds 10 year limit (n = 288)
Full text not available (n = 7)
Conference abstract only (n = 54)
no DF or DFSPs evaluated (n = 8)
Details of IHC data not reported (n = 19)
Insufficient number of DFs or DFSPs (n = 16)
Assessment of stromal compartment only (n = 2)
Full text not available in
English, French or Spanish (n = 6)
Included
Studies included in review (n = 63)

Figure 2.


MARKERS ASSESSED IN ALL STUDIES (n=63)
CD34
SMA
S100
FXIIIa
Desmin, Ki67
ALK, CD68
VIM, EMA
CD99, PanCK
PDGFb, CD10, D240, P53, STAT6, TFE3, BCL-2
MelanA, Nestin, p16, p63, PDGFRb, CCND1,CD163,ER, ERG, H3K27me3,PR,TLE1
Akt,BCOR,CD105,CD117,CD11c,CD133,CD31,CD4,CD45, Cx43,EGFR,ERK,EVG,EZH2,FAM118B,FGFR1,FGFR2,FGFR3, FGFR4,FOSB,GRIA2,H3K27me2,HMB45,LSP1,Lysozyme,MITF, MMP9,MSA,mTOR,MUC4,NCID,NKIC3,NTRK,Oct3/4,p4EBP1, P53,P75,pAkt,PDGFB,PDGFRb,PDL1,PHH3,pmTOR,pPDGFRa, pPDGFRb,PRAME,pS6RP,S100A6,SMAD3,SOX10,SOX9,STAT3, TLK2,VEGF,WT1,TGFb,PDGFRa,Fibronectin,TGFRb-1, TGFRb-2,VDR,Myogenin,FGF2
0
5
10
15
20
25
30
Frequency of marker evaluation in studies

Figure 3.


MARKERS ASSESSED IN STUDIES FOCUSED ON DISTIGUISHING DF FROM DFSP (n=15)
CD34
FXIIIa
ALK
ERG,D240,CD99,CD68,CD10
WT1,VIM,S100A6,S100,PHH3,PDGFRb,PDGFb, P75,Oct3/4,MelanA,LSP1,Ki67,FGFR14,FGF2, Cx43,CD133,CD117,CD105,CCND1
0
1
2
3
4
5
6
7
Frequency of marker evaluation in studies